Researchers observe no association between prostate cancer and urethritis, orchitis, or epididymitis.
Radiation treatment is associated with an increased risk of requiring minimally invasive urologic procedures.
In a phase 2 trial, enzalutamide treatment was associated with significantly longer progression-free survival.
Age-adjusted prostate cancer-specific comorbidity index strongly predictive of other-cause mortality.
Each 20-unit increment in GPS was associated with a more than 2-fold increased likelihood of recurrence.
They are more likely to die and suffer complications compared with those admitted on weekdays.
The treatment was most effective in relief of macroscopic hematuria.
Researchers observed greater incidences of colorectal cancer among patients who underwent bilateral orchiectomy, surgery, and ADT.
A PHI of 82 discriminated between patients with and without biochemical recurrence.
Factors include younger age, aggressive disease, and concern that their malignancy is uncontrollable.
Smoking cessation for 10 or more years, however, mitigates that risk.
Androgen receptor splice variant 7 (AR-V7) detection may serve as treatment biomarker in castration-resistant prostate cancer (CRPC).
Researchers observed increases in components of metabolic syndrome and in the prevalence of full metabolic syndrome among men with prostate cancer treated with ADT.
Men most wedded to a "western" diet of red and processed meat and refined grains were more than two-and-a-half-times more likely to die from a prostate cancer-related cause.
In a study of high-risk PCa patients, the statin-metformin combo was associated with a 43% reduction in risk compared with non-use of the medications.
Findings among men treated for localized prostate cancer.
Two-thirds of patients feel that tumor profiling could improve their treatment; many will pay out of pocket.
The combination improved oncologic control better than dose-escalated radiotherapy alone in men with intermediate-risk prostate cancer.
Men with a particular gene mutation affected most, researchers find.
Primary care screening patterns have changed as a result of the USPSTF recommendation.
Study reveals comparable rates of freedom from biochemical failure at 5 years.
This effect appears to occur mainly in men who experience recurrence when they are younger than 65 and in those with low-risk cancer.
Biopsies triggered by an abnormal DRE alone were significantly less likely to detect clinically significant prostate cancer than biopsies triggered by an abnormal PSA alone.
Gleason 9-10 tumors are associated with a greater risk of biochemical and clinical recurrence, but not overall survival.
Researchers report on a study in which survivors were followed up for a median of 14 years.
Researchers concluded that margin status is a surrogate for established risk criteria.
Neutrophil-lymphocyte ratio could have a prognostic role in localized prostate cancer.
The 10-year rates of biochemical and clinical recurrence are comparable to those of open surgery.
A PSA doubling time of less than 3 years and a Gleason score of 8-10 were associated with an increased risk of metastasis.
Recent study shows that 71% of prostate cancer patients with very-low-risk disease were placed on active surveillance.
- Dietary Interventions Improve Hyperphosphatemia Treatment
- Genomic Prostate Score Predicts PCa Recurrence, Adverse Pathology
- New Dyslipidemia Guidelines Eliminate Treatment Targets
- Dysfunctional HDL May Contribute to Excess CVD Risk in CKD Patients
- Weekend Hospitalizations Worsen Outcomes for Metastatic PCa Patients
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)